Weill Medical College Of Cornell University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1865-01-01

Employees: -

Market Cap: -

Website: http://weill.cornell.edu

Clinical Trials

Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: thalomid
Drug: lenalidomide
Drug: clarithromycin
Drug: dexamethasone

First Posted Date: 2007-10-03

Last Posted Date: 2021-05-24

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 26

Registration Number: NCT00538733

Locations: 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States

Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: dexamethasone
Drug: thalidomide
Drug: lenalidomide

First Posted Date: 2007-10-03

Last Posted Date: 2018-06-06

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 5

Registration Number: NCT00538824

Locations: 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States

Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: 117Lu-J591

First Posted Date: 2007-10-03

Last Posted Date: 2021-03-19

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 55

Registration Number: NCT00538668

Locations: 🇺🇸
Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States

Dasatinib in Polycythemia Vera

Phase 2

Terminated

Conditions: Polycythemia Vera

Interventions: Drug: Dasatinib

First Posted Date: 2007-10-03

Last Posted Date: 2017-06-20

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 10

Registration Number: NCT00538980

Locations: 🇺🇸
Weill Cornell Medical College - New York Presbyterian Hospital, New York, New York, United States
🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
The Jones Clinic, Germantown, Tennessee, United States

and more 1 locations

Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

First Posted Date: 2007-10-03

Last Posted Date: 2011-06-30

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 30

Registration Number: NCT00538876

Locations: 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States

Diagnostic Utility of Contrast Echocardiography for Detection of LV Thrombi Post ST Elevation Myocardial Infarction

Completed

Conditions: Thrombus
Myocardial Infarction

First Posted Date: 2007-10-03

Last Posted Date: 2018-02-14

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 250

Registration Number: NCT00539045

Locations: 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States

Effect of Steroids on Gene Expression in the Healthy Smokers Lungs

Phase 4

Withdrawn

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Beclomethasone

First Posted Date: 2007-09-20

Last Posted Date: 2016-05-04

Lead Sponsor: Weill Medical College of Cornell University

Registration Number: NCT00532584

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

fMRI Investigation of Depression in Patients With Epilepsy

Withdrawn

Conditions: Epilepsy
Depression

First Posted Date: 2007-09-20

Last Posted Date: 2009-02-10

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 250

Registration Number: NCT00532376

Locations: 🇺🇸
Citigroup Biomedical Imaging Center at 516 East 72nd Street, New York, New York, United States

Placement of Permanent Pacemaker Study

Completed

Conditions: Cardiac Surgical Procedures

First Posted Date: 2007-08-07

Last Posted Date: 2017-01-19

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 500

Registration Number: NCT00512161

Locations: 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States

Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL

Phase 2

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: bortezomib, dexamethasone, ifosfamide
Drug: mesna, cisplatin, etoposide, rituximab

First Posted Date: 2007-07-20

Last Posted Date: 2017-04-07

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 15

Registration Number: NCT00504751

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy